Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Free Cash Flow (2017 - 2025)

Historic Free Cash Flow for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to -$105.9 million.

  • Denali Therapeutics' Free Cash Flow fell 6806.25% to -$105.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$410.8 million, marking a year-over-year decrease of 935.77%. This contributed to the annual value of -$363.6 million for FY2024, which is 197.45% up from last year.
  • Latest data reveals that Denali Therapeutics reported Free Cash Flow of -$105.9 million as of Q3 2025, which was down 6806.25% from -$79.6 million recorded in Q2 2025.
  • In the past 5 years, Denali Therapeutics' Free Cash Flow registered a high of -$43.3 million during Q3 2021, and its lowest value of -$136.5 million during Q1 2025.
  • Moreover, its 5-year median value for Free Cash Flow was -$77.5 million (2022), whereas its average is -$81.0 million.
  • As far as peak fluctuations go, Denali Therapeutics' Free Cash Flow tumbled by 688532.26% in 2021, and later skyrocketed by 2952.89% in 2024.
  • Denali Therapeutics' Free Cash Flow (Quarter) stood at -$68.5 million in 2021, then fell by 13.08% to -$77.5 million in 2022, then plummeted by 30.16% to -$100.9 million in 2023, then increased by 11.98% to -$88.8 million in 2024, then dropped by 19.27% to -$105.9 million in 2025.
  • Its Free Cash Flow stands at -$105.9 million for Q3 2025, versus -$79.6 million for Q2 2025 and -$136.5 million for Q1 2025.